Dublin, Jan. 15, 2018 (GLOBE NEWSWIRE) -- The "Inhalation Drug Delivery Devices Market" report has been added to ResearchAndMarkets.com's offering.
The combined market for inhalation drug delivery devices totaled nearly $11.7bn in 2016, and is expected to climb at a rate of 1.2% over the forecast period.
The combined prevalence of asthma and COPD in the countries covered by this report (US, Japan, and five major EU markets of France, Germany, Italy, Spain, and the UK) is 109.3 million.
Generic erosion will be a key factor in limiting growth in the overall market; however, increasing disease prevalence and the introduction of novel products such as triple combination therapies will offset declines. The US accounts for nearly two-thirds of the overall inhalation drug delivery devices market, and is expected to experience the most growth over the forecast period as its population increases and ages.
This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the inhalation drug delivery devices markets, including MDIs, DPIs, and nebulizers for the treatment of asthma and COPD.
Key Questions Answered
- What are the key drivers and limiters to the inhalation drug delivery devices market?
- Which competitors are leading the market and introducing new technology?
- How are technological advancements impacting market growth?
- What factors are driving epidemiologic growth in the inhalation drug delivery devices market?
Inhalation Market Highlights
- The combined prevalence of asthma and COPD in the countries covered by this report (US, Japan, and five major EU markets of France, Germany, Italy, Spain, and the UK) is 109.3 million.
- The combined market for inhalation drug delivery devices totaled nearly $11.7bn in 2016, and is expected to climb at a rate of 1.2% over the forecast period.
- Generic erosion will be a key factor in limiting growth in the overall market; however, increasing disease prevalence and the introduction of novel products such as triple combination therapies will offset declines.
- The US accounts for nearly two-thirds of the overall inhalation drug delivery devices market, and is expected to experience the most growth over the forecast period as its population increases and ages.
Key Topics Covered:
Executive Summary
- Respiratory disease prevalence
- Inhalation drug delivery devices market
- Selected market drivers and limiters
- Asthma-related devices segment
- COPD-related devices segment
- Market leaders
- Emerging competition
1. Inhalation Drug Delivery Technology
1.1 Technology
- Metered dose inhalers
- Breath-actuated MDIs
- Spacers for use with MDIs
- Dry powder inhalers
- Nebulizers
2. Inhalation Devices for Asthma
2.1 Epidemiology
2.2 Products
- Regulatory guidelines
- AstraZeneca
- Boehringer Ingelheim
- GlaxoSmithKline
- Merck & Co
- SkyePharma/Vectura
- Emerging products
2.3 Market analysis
- Advair and Breo
- Dulera
- Flutiform
- Spiriva
- Symbicort
- Combined market forecast
- US market forecast
- 5EU market forecast
- Japan market forecast
2.4 Bibliography
3. Inhalation Devices for Chronic Obstructive Pulmonary Disease
3.1 Epidemiology
3.2 Products
- AstraZeneca
- Boehringer Ingelheim
- GlaxoSmithKline
- Merck & Co
- Novartis
- Sunovion Pharmaceuticals
- Teva
- Emerging products
3.3 Market analysis
- Duaklir, PT010, Symbicort, and Tudorza
- Spiriva, Stiolto, and Striverdi
- CHF 5993
- Advair, Breo, Anoro, FF/UMEC/VI, and Incruse
- Dulera
- Arcapta, Seebri, Utibron
3.4 Bibliography
For more information about this report visit https://www.researchandmarkets.com/research/rkp6gx/global_inhalation?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Delivery
